GRIFFIN MICHELLE RENEE 4
4 · Adaptive Biotechnologies Corp · Filed Jun 29, 2026
Research Summary
AI-generated summary of this filing
Adaptive Biotechnologies ADPT Director Michelle Griffin Exercises & Sells Shares
What Happened Michelle Renee Griffin, a director of Adaptive Biotechnologies (ADPT), exercised 52,084 stock options at $7.80 per share (cost ~$406,255) on June 25, 2026 and immediately sold the 52,084 shares in the open market the same day for a weighted-average price of $20.18 per share (gross proceeds ~$1,051,055). A separate derivative entry at $0 reflects the conversion/disposition of the option instrument upon exercise. This sequence (exercise then sale) is effectively a cashless exercise and sale — the exercise provided shares that were promptly sold.
Key Details
- Transaction date: June 25, 2026; Form 4 filed June 29, 2026 (timely).
- Exercise: 52,084 options exercised at $7.80 each; cash paid ≈ $406,255.
- Sale: 52,084 shares sold at a weighted-average price of $20.18; gross proceeds ≈ $1,051,055. Individual sale prices ranged $20.00–$20.55.
- Footnotes: Transactions were executed under a Rule 10b5-1 trading plan adopted Nov 7, 2025. The option was fully vested and exercisable.
- Shares owned after the transaction: Not specified in the provided filing excerpt.
Context Because the exercise and sale occurred the same day and the filing notes a 10b5-1 plan, this appears to be a prearranged (automated) sale rather than an ad-hoc market-timing trade. For retail investors, purchases generally carry more informational weight than routine, plan-driven sales; here the activity represents monetization of vested options rather than an added personal investment.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-06-25$7.80/sh+52,084$406,255→ 67,709 total - Sale
Common Stock
[F1][F2]2026-06-25$20.18/sh−52,084$1,051,055→ 15,625 total - Exercise/Conversion
Stock Option (right to buy)
[F1][F3]2026-06-25−52,084→ 0 totalExercise: $7.80Exp: 2029-04-23→ Common Stock (52,084 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
- [F2]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F3]The option was fully vested and exercisable.